Corporate Banner
Satellite Banner
Proteomics
Scientific Community
 
Become a Member | Sign in
Home>News>This Article
  News
Return

Biomarkers Indicate Increased Risk of Death After Discharge from Cardiac Surgery

Published: Monday, December 23, 2013
Last Updated: Monday, December 23, 2013
Bookmark and Share
Following cardiac surgery, patients with elevated levels of kidney injury biomarkers are at a significantly higher risk of dying during the next three years, a Yale study has found.

An earlier Yale study identified specific blood and urine markers that can predict which patients will suffer acute kidney injury (AKI) after cardiac surgery. AKI is a frequent complication of cardiac surgery, and the Yale investigators demonstrated that biomarkers predicted who is at risk of progressively worsening kidney function immediately after surgery.

The new study examined mortality at an average of three years after cardiac surgery. The researchers found that patients with clinically apparent AKI who also had high levels of urinary biomarkers of kidney injury, particularly interleukin (IL)-18 and kidney injury molecule (KIM)-1, faced a 2- to 3.2-fold increased risk for mortality over three years, compared with patients with the lowest levels of these biomarkers. However, the most interesting finding, say the researchers, was that even patients who have no evidence of clinical AKI, but who do have high levels of these injury biomarkers in their urine were also at higher risk of death.

The researchers believe these findings can provide an important way to assess patients — both with and without clinical AKI — in the immediate postoperative period in order to identify those who are at increased risk of death.

“AKI has traditionally been defined by serum creatinine, which represents changes in kidney function. This is the first study that links structural injury of the kidney with meaningful long-term outcomes,” said senior author Chirag Parikh, M.D., director of the Program of Applied Translational Research and associate professor of nephrology at Yale School of Medicine and the Veterans Affairs Medical Center. “These newer biomarkers of kidney injury, often referred to as the ‘troponins of the kidney,’ have the potential to shape the future definitions and trials of acute kidney injury.”

The Yale researchers, along with those from other institutions in the United States and Canada, are known as the Translational Research Investigating Biomarker End-Points in AKI consortium (TRIBE-AKI), a multidisciplinary group of academic investigators with expertise in pre-clinical, translational, epidemiological, and health services research.

First author is Steven Coca of Yale; other authors are Harlan Krumholz of Yale; Amit Garg, and Heather Thiessen-Philbrook of Western University in London, Ontario; Jay Koyner of the University of Chicago; Uptal Patel of Duke University; and Michael Shlipak of the Veterans Affairs Medical Center at the University of California, San Francisco.

This study was supported by grants from the National Institutes of Health (R01HL085757, K23DK080132, and K24DK090203), and from Abbott Diagnostics, and Sekisui Diagnostics, Inc.

The results appear in the Journal of the American Society of Nephrology.


Further Information

Join For Free

Access to this exclusive content is for Technology Networks Premium members only.

Join Technology Networks Premium for free access to:

  • Exclusive articles
  • Presentations from international conferences
  • Over 3,000+ scientific posters on ePosters
  • More than 4,500+ scientific videos on LabTube
  • 35 community eNewsletters


Sign In



Forgotten your details? Click Here
If you are not a member you can join here

*Please note: By logging into TechnologyNetworks.com you agree to accept the use of cookies. To find out more about the cookies we use and how to delete them, see our privacy policy.

Related Content

New Type of Drug Can Target All Disease-causing Proteins
Current drugs block the actions of only about a quarter of known disease-causing proteins, but Yale University researchers have developed a technology capable of not just inhibiting, but destroying every protein it targets.
Monday, June 15, 2015
Single-Cell, 42-plexed Protein Analysis Achieved with a New Microchip Technology
A novel microdevice capable of detecting 42 unique immune effector proteins has been developed.
Tuesday, February 17, 2015
Tarantula Venom Holds Hope for New Painkillers
Screening more than 100 spider toxins, Yale researchers identified a protein from the venom of the Peruvian green velvet tarantula that blunts activity in pain-transmitting neurons.
Monday, February 17, 2014
Alzheimer’s Missing Link Found: Is a Promising Target for New Drugs
Researchers have discovered a protein that is the missing link in the complicated chain of events that lead to Alzheimer’s disease.
Monday, September 09, 2013
Lung Disease and Melanoma: a Common Molecular Mechanism?
Researchers have solved a biological mystery about the common genesis of many serious diseases such as asthma and metastatic melanoma.
Monday, September 02, 2013
Yale Nobel Laureate Honored with Connecticut Medal of Science
Thomas Steitz will receive the 2013 Connecticut (CT) Medal of Science, the state’s top prize for technological achievement crucial to economic development.
Monday, April 22, 2013
Bacteria Yield Clues About Why Proteins go Bad in ALS and Alzheimer’s
Scientists are unsure why proteins form improperly and cluster together in bunches, a hallmark of neurodegenerative diseases.
Friday, November 02, 2012
Yale Scientists Find a Way to Make Disease-Causing Proteins Vulnerable to Drugs
Researchers have identified a novel way to design drugs for previously inaccessible proteins.
Friday, July 27, 2012
Yale Scientists Pinpoint Key Ingredient in Fighting Pneumonia
Study shows that a mysterious protein produced by a wide spectrum of living things is crucial in regulating the immune response to the most common form of pneumonia.
Friday, July 20, 2012
Yale Researchers Awarded Grant to Develop Treatment of Williams Syndrome
A $320,000 grant will be utilized to study the elastin gene in order to design new treatments for Williams Syndrome.
Wednesday, October 28, 2009
Researchers Announce that two Proteins have Unexpected Effects on Autoimmune Diseases Such as Lupus
Drugs that target these proteins could be important therapies for autoimmunity.
Wednesday, November 01, 2006
Scientific News
HIV Particles Used to Trap Intact Mammalian Protein Complexes
Belgian scientists from VIB and UGent developed Virotrap, a viral particle sorting approach for purifying protein complexes under native conditions.
Potential “Good Fat” Biomarker
New method to measure the activity of energy consuming brown fat cells could ease the testing weight loss drugs.
Computational Model Finds New Protein-Protein Interactions
Researchers at University of Pittsburgh have discovered 500 new protein-protein interactions (PPIs) associated with genes linked to schizophrenia.
New Insights into Gene Regulation
Researchers have solved the three-dimensional structure of a gene repression complex that is known to play a role in cancer.
Controlling RNA in Living Cells
Modular, programmable proteins can be used to track or manipulate gene expression.
Soy Shows Promise as Natural Anti-Microbial Agent
Soy isoflavones and peptides may inhibit the growth of microbial pathogens that cause food-borne illnesses, according to a new study from University of Guelph researchers.
Potential Target for Revolutionary Antibiotics
An international team of including the Lomonosov Moscow State University researchers discovered which enzyme enables Escherichia coli bacterium (E. coli) to breathe.
DNA Barcodes Gone Wild
A team of researchers at University of Toronto’s Donnelly Centre and Sinai Health System’s Lunenfeld-Tanenbaum Research Institute (LTRI) has developed a new technology that can stitch together DNA barcodes inside a cell to simultaneously search amongst millions of protein pairs for protein interactions.
Biomarkers for Profiling Prostate Cancer Patients
Exiqon A/S has announced the publication of validation of prognostic microRNA biomarkers for the aggressiveness of prostate cancer in independent cohorts.
Grant to Fund Million Peaks Project
The European Research Council (ERC) has awarded a prestigious Advanced Grant to Prof. Peter Schoenmakers, Prof. Albert Polman and Prof. Huib Bakker, all three of whom work at the University of Amsterdam (UvA).
Scroll Up
Scroll Down
SELECTBIO

Skyscraper Banner
Go to LabTube
Go to eposters
 
Access to the latest scientific news
Exclusive articles
Upload and share your posters on ePosters
Latest presentations and webinars
View a library of 1,800+ scientific and medical posters
3,000+ scientific and medical posters
A library of 2,500+ scientific videos on LabTube
4,500+ scientific videos
Close
Premium CrownJOIN TECHNOLOGY NETWORKS PREMIUM FOR FREE!